Market Overview

Canaccord Genuity Reiterates Buy Rating, $20.50 PT on Vascular Solutions on Guardian Recall

Related VASC
What Makes Vascular Solutions (VASC) a Strong Sell? - Tale of the Tape
Vascular Solutions Enters Into Agreement With U.S. Army to Develop Freeze-Dried Plasma Product

In a report published Monday, Canaccord Genuity analyst Jason R. Mills reiterated a Buy rating and $20.50 price target on Vascular Solutions (NASDAQ: VASC).

In the report, Mills noted, “Vascular Solutions announced that it initiated a voluntary recall on February 28 for the Guardian II and Guardian II NC hemostasis valves used in catheterization procedures due to the potential for air leaks. VASC indicated that no injuries have been reported in association with this issue. In addition, the FDA has classified this action as a Class 1 recall. Although the timing of an FDA review and validation of the modified (i.e. fixed) product has not been determined, the company anticipates re-launching Guardian in the U.S. in mid- to late April. We note that the Guardian product line generates ~$2M in annual sales, representing <2% of total projected sales for 2013.”

Vascular Solutions closed on Friday at $15.00.

Latest Ratings for VASC

DateFirmActionFromTo
Mar 2013Piper JaffrayInitiates Coverage onOverweight
Feb 2013BenchmarkDowngradesBuyHold
Jan 2013Sidoti & Co.DowngradesBuyNeutral

View More Analyst Ratings for VASC
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings

 

Related Articles (VASC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters